Claims
- 1. A compound of the formula ##STR5## wherein m is 0, 1 or 2; R.sub.1, R.sub.2, R.sub.3 and R.sub.7 are taken from the group consisting of hydrogen, hydroxy, loweralkyl, loweralkoxy, halo, amino, acetamido or NHSO.sub.2 R wherein R is taken from the group consisting of hydrogen or loweralkyl, provided that R.sub.1, R.sub.2, R.sub.3 and R.sub.7 cannot simultaneously be hydrogen or halo, and provided that when one of R.sub.1, R.sub.2, R.sub.3 and R.sub.7 is halo, the others cannot simultaneously be hydrogen and when two of R.sub.1, R.sub.2, R.sub.3 and R.sub.7 are halo, the other two cannot simultaneously be hydrogen and when three of R.sub.1, R.sub.2, R.sub.3 and R.sub.7 are halo, the other cannot simultaneously be hydrogen, and provided that R.sub.1 and R.sub.7 cannot simultaneously be methoxy each when R.sub.2 and R.sub.3 are hydrogen; R.sub.1 and R.sub.2 or R.sub.2 and R.sub.3 or R.sub.3 and R.sub.7 taken together can form a methylenedioxy or ethylenedioxy ring, or R.sub.1 and R.sub.2 or R.sub.2 and R.sub.3 or R.sub.3 and R.sub.7 taken together with the aromatic ring can form a benzimidazole or indole ring; and R.sub.4 and R.sub.5 are hydrogen or taken together form a closed ring of the formula ##STR6## wherein n is 1 or 2, and the combined solid and dashed line represents a single or double bond when n is 1, and R.sub.6 is taken from the group consisting of hydrogen or loweralkyl, or a pharmaceutically acceptable salt thereof.
- 2. The compound in accordance with claim 1 wherein m is 1 and n is 1.
- 3. The compound in accordance with claim 1 wherein m is 2 and n is 1.
- 4. The compound in accordance with claim 1 wherein m is 2 and n is 2.
- 5. The compound in accordance with claim 2 wherein R.sub.1 and R.sub.2 are each hydroxy.
- 6. The compound in accordance with claim 3 wherein R.sub.1 and R.sub.2 are each hydroxy.
- 7. The compound in accordance with claim 3 wherein R.sub.1 and R.sub.3 are each methoxy.
- 8. The compound in accordance with claim 2 wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.7 are taken from the group consisting of hydrogen, hydroxy or methoxy.
- 9. The compound in accordance with claim 2 wherein R.sub.1 and R.sub.2 are taken together to form a methylenedioxy ring.
- 10. The compound in accordance with claim 2 wherein R.sub.1 and R.sub.2 are each hydroxy.
- 11. The compound in accordance with claim 2 wherein R.sub.1 and R.sub.2 taken together with the aromatic ring form a benzimidazole ring wherein R.sub.6 is hydrogen.
- 12. The compound in accordance with claim 4 wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.7 are taken from the group consisting of hydrogen, hydroxy or methoxy.
- 13. The compound in accordance with claim 4 wherein R.sub.1 and R.sub.2 form a methylenedioxy ring.
- 14. A composition with alpha-adrenergic activity in pharmaceutical dosage containing a carrier and a therapeutically effective amount of a compound of the formula of claim 1.
- 15. A method of treating hypertension which comprises administering to a patient a therapeutically effective amount of a compound of the formula of claim 1.
BACKGROUND OF THE INVENTION
This application is a continuation-in-part of application Ser. No. 617,770 filed June 6, 1984, now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3354175 |
Fruhstorfer et al. |
Nov 1967 |
|
4499105 |
Panneman |
Feb 1985 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
877306 |
Sep 1961 |
GBX |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
617770 |
Jun 1984 |
|